ETFs
B
BCRX
Biocryst Pharmaceuticals Inc
9.02
-0.36-3.84%After Hours: 9.05 +0.03 +0.34%19:58 04/02 EDT
OPEN/PREV CLOSE9.31/9.38
TODAY RANGE8.92-9.35
VOL7.82M
MARKET CAP2.26B
52 WEEK RANGE6.00-11.31
AVG VOL (3M)5.55M
% TURNOVER3.12%
TURNOVER--
P/E (TTM)7.47
% RANGE4.58%
EPS(TTM)1.207
P/E(FORWARD)33.41
P/B-16.1302
BVPS-0.5592
DIVIDEND--
P/S2.197
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.19B
SHARES OUTSTANDING250.80M
NEXT EARNINGS05/04-05/08
FREE FLOAT242.61M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·03/28 13:01
EOG, GitLab, StoneCo, Cipher, BioCryst Insider Shake-Up
Simply Wall St·03/26 17:09
Does BioCryst Pharmaceuticals (BCRX) Still Offer Value After Recent Share Price Strength?
TipRanks·03/25 11:17
RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)
TipRanks·03/25 02:02
Major Insider Move at BioCryst Shakes Up Investor Buzz
Reuters·03/24 20:04
BioCryst director Theresa Heggie disposes of USD 504,000 in common shares
Benzinga·03/24 09:31
Why Paranovus Entertainment Technology Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
Seeking Alpha·03/19 18:37
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Simply Wall St·03/18 14:15
Is It Time To Reconsider BioCryst Pharmaceuticals (BCRX) After Recent Share Price Strength
TipRanks·03/17 18:38
3 Best Value Stocks with Over 20% Upside in 2026, According to Analysts
Seeking Alpha·03/17 14:58
BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real
Seeking Alpha·03/16 15:15
BioCryst gains amid takeover speculation
Same Industry
Name/Symbol
Change%
Price